ClinicalTrials.gg
Not yet recruitingNCT07735481Updated Aug 5, 2026

Promoting Recovery by Overcoming Self-stigma in Mental Health Disorders With a Narrative Enhancement and Cognitive Therapy (NECT) Group Intervention

An interventional study of Narrative Enhancement Cognitive Therapy and Control Group Sessions in Mental Disorders and Substance Use Disorders, sponsored by Louise Penzenstadler. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Louise Penzenstadler · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate whether Narrative Enhancement and Cognitive Therapy (NECT) can promote recovery among adults living with severe mental health disorders, including substance use disorders. NECT is a structured group intervention that combines education about stigma, cognitive techniques to challenge internalized negative beliefs, and narrative exercises that help participants develop a broader identity beyond their diagnosis.

Approximately 106 adults receiving outpatient or day-hospital psychiatric care at Geneva University Hospitals will be randomly assigned to receive either usual care plus 12 weekly NECT sessions or usual care plus 12 comparison group sessions that do not specifically address self-stigma or recovery. The study will examine whether NECT improves recovery after the intervention and whether any benefits are maintained over time.

Read the detailed description

Self-stigma occurs when people internalize negative societal stereotypes about mental illness. It can contribute to shame, reduced self-esteem, hopelessness, social withdrawal, lower treatment engagement, and difficulties pursuing personal goals. Although recovery-oriented mental health care increasingly emphasizes empowerment, resilience, social inclusion, and quality of life, interventions specifically targeting self-stigma are not yet routinely available. This is particularly relevant for people with substance use disorders, who may experience strong moral judgment and stigmatizing attitudes.

Narrative Enhancement and Cognitive Therapy is a manualized, recovery-oriented group intervention developed to reduce self-stigma. The programme combines psychoeducation about stigma and common misconceptions, cognitive restructuring of negative beliefs about oneself, and narrative exercises in which participants reflect on and share personal experiences. Its purpose is to help participants develop a more integrated understanding of themselves that is not defined solely by mental illness. Previous studies have reported beneficial effects in people with psychotic disorders, but evidence remains limited for other psychiatric populations and for people with substance use disorders. The French-language programme has not yet been evaluated in routine clinical practice.

The study will use a prospective, multicentre, randomized controlled design with an additional qualitative component. Approximately 106 adults with psychiatric disorders will be recruited from three specialized outpatient or day-hospital settings within the Department of Psychiatry at Geneva University Hospitals. Participants will be randomly allocated in a 1:1 ratio to an intervention or control condition. Randomization will be stratified by participating centre.

Participants assigned to the intervention condition will continue their usual psychiatric care and attend 12 weekly NECT group sessions. Participants assigned to the control condition will continue their usual care and attend 12 weekly group sessions that do not include specific psychotherapeutic or psychoeducational content addressing self-stigma or recovery. The comparison sessions may focus, for example, on participants' weekly activities.

NECT will be delivered in groups of approximately eight participants. Each 90-minute session will be facilitated by two trained co-facilitators, including a mental health professional and a peer practitioner. The programme includes an introductory session, psychoeducation, cognitive restructuring, narrative enhancement, and a concluding session. Participants who miss a session may be offered an individual make-up session to review the content and reduce the risk of discontinuing the programme.

The main objective is to determine whether participation in NECT improves personal recovery compared with the control condition. The study will also examine whether any changes are maintained approximately six months after the intervention and whether NECT influences self-stigma, empowerment, quality of life, self-esteem, self-compassion, psychological flexibility, psychiatric symptoms, and substance use.

In addition to the quantitative evaluation, participants who receive NECT may take part in semi-structured interviews after the intervention. These interviews will explore how participants experienced the programme, what they found useful, and how changes in self-stigma may contribute to recovery. The qualitative findings will complement the quantitative results and help inform the possible future implementation of NECT in routine psychiatric and addiction services.

02

Conditions studied

  • Mental Disorders
  • Substance Use Disorders

Keywords

  • Narrative Enhancement and Cognitive Therapy
  • Self stigma
  • Recovery
  • Substance use disorders
  • Transdiagnostic group intervention
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 106 is close to the median of 100 across 1,305 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Louise Penzenstadler is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • psychiatric diagnosis within F10-F48, F60-F69, or F90, including substance use disorders
  • Receiving outpatient or day-hospital treatment
  • Diagnosed or in treatment for at least 12 months
  • Clinically stable for at least 3 months, with stable pharmacological treatment during this period
  • Clinical Global Impressions-Severity score below 6

Exclusion criteria

Exclusion Criteria:

  • Participation in another program likely to affect social functioning or self-stigma, such as social cognitive remediation or social skills training
  • Acute psychiatric episode with a Clinical Global Impressions-Severity score above 6
  • Medical emergency or immediate life-threatening situation at inclusion
  • Unable to provide
  • Comorbid intellectual disability
  • Receiving care under constraint or deprived of liberty by judicial order Insufficient ability to speak and read French
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    NECT

    Treatment as usual plus 12 weekly 90-minute NECT group sessions combining psychoeducation, cognitive restructuring, and narrative exercises to reduce self-stigma and support recovery.

    Behavioral: Narrative Enhancement Cognitive Therapy

  • Active comparator
    Control Group

    Treatment as usual plus 12 weekly group sessions without specific psychotherapeutic or psychoeducational content targeting self-stigma or recovery

    Behavioral: Control Group Sessions

Interventions

  • BehavioralNarrative Enhancement Cognitive Therapy

    NECT is a manualized group intervention comprising 12 weekly 90-minute sessions delivered to groups of approximately eight participants. It combines psychoeducation about stigma and self-stigma, cognitive restructuring of internalized negative beliefs, and narrative exercises that help participants develop a more integrated identity beyond mental illness. Sessions are co-facilitated by a trained mental health professional and a peer practitioner. Individual make-up sessions may be offered for missed sessions.

  • BehavioralControl Group Sessions

    Twelve weekly group sessions in which participants discuss topics such as their weekly activities, without specific psychotherapeutic or psychoeducational content targeting self-stigma or recovery. Treatment as usual continues throughout.

06

What researchers measure

Primary outcomes

  1. Change in personal recovery measured by the Recovery Assessment Scale

    Personal recovery will be assessed using the Recovery Assessment Scale (RAS). The total score ranges up to 205, with higher scores indicating greater recovery. An increase of at least 14 points is considered clinically meaningful.

    Time frame: Baseline to post-intervention, approximately 12 weeks.

Secondary outcomes

  1. Change in personal recovery at follow-up

    Personal recovery measured with the Recovery Assessment Scale. The total score ranges up to 205, with higher scores indicating greater recovery. An increase of at least 14 points is considered clinically meaningful.

    Time frame: Baseline to approximately 6 months after the intervention.

  2. Change in self-stigma

    Self-stigma measured with the 29-item Internalized Stigma of Mental Illness Scale. Items are rated from 1 to 4 and combined into a mean total score ranging from 29 to 116. The stigma-resistance items are reverse-scored. Higher scores indicate greater internalized stigma and therefore a worse outcome.

    Time frame: Baseline, post-intervention, and approximately 6 months after the intervention.

  3. Change in empowerment

    Sense of empowerment measured with the 28-item Empowerment Scale. an overall mean score will be calculated, ranging from 28 to 112. Higher scores indicate greater perceived empowerment and therefore a better outcome.

    Time frame: Baseline, post-intervention, and approximately 6 months after the intervention.

  4. Change in quality of life

    Subjective quality of life measured with the 26-item WHO Quality of Life-BREF. Scores will be calculated separately for the physical health, psychological health, social relationships, and environment domains and transformed to a scale ranging from 0 to 100. Higher scores indicate better quality of life and therefore a better outcome.

    Time frame: Baseline, post-intervention, and approximately 6 months after the intervention.

  5. Change in self-compassion

    Self-compassion measured with the 26-item Self-Compassion Scale. The total score is ranging from 26 to 130. Higher scores indicate greater self-compassion and therefore a better outcome.

    Time frame: Baseline, post-intervention, and approximately 6 months after the intervention.

  6. Change in psychological flexibility

    Psychological flexibility measured with the 10-item Acceptance and Action Questionnaire-II. Items are rated from 1 to 7 and summed to produce a total score ranging from 10 to 70. Higher scores indicate greater psychological inflexibility and experiential avoidance and therefore a worse outcome.

    Time frame: Baseline, post-intervention, and approximately 6 months after the intervention.

  7. Change in psychiatric symptoms

    Psychiatric symptoms measured with the 23-item DSM-5 Cross-Cutting Symptom Measure, Levels 1. It assesses 13 psychiatric symptom domains. Each item is rated from 0 to 4, and the highest item score within each domain is used as the domain score. Each domain score therefore ranges from 0 to 4. Higher scores indicate greater symptom frequency or severity and therefore a worse outcome. There is no single total score for this measure. The scores should be reported by domain.

    Time frame: Baseline, post-intervention, and approximately 6 months after the intervention.

  8. Change in substance use

    Substance use will be assessed using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Level 2-Substance Use. Each substance-specific item is rated from 0 to 4, where 0 indicates no use and 4 indicates use nearly every day during the previous two weeks. Higher item scores indicate more frequent substance use and therefore a worse outcome. Individual substance items will be interpreted separately rather than as a single overall scale score.

    Time frame: Baseline, post-intervention at approximately 12 weeks, and 6 months after the intervention.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — A decision regarding the sharing of de-identified individual participant data has not yet been made. Data sharing will depend on applicable ethical and data-protection requirements, participant consent, and approval by the study investigators and relevant institutions.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.

Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 23 months is below that.

Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 30, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2029
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07735481
Lead sponsor
Louise Penzenstadler
Responsible party
Louise Penzenstadler (Principal investigator, University Hospital, Geneva) — Sponsor-investigator
First posted
Jul 30, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Aug 5, 2026

Study contacts

Louise Penzenstadéer, MD
Contact
louise.penzenstadler@hug.ch
+41223725750
Hélène Richard-Lépouriel, MD
Contact
helene.richard-lepouriel@hug.ch
+41223054511

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion